Implementing Our Microsurgical Breast Reconstruction Enhanced Recovery after Surgery Pathway: Consensus Obstacles and Recommendations

Jill P. Stone, MD, FRCSC*
Charalampos Siotos, MD*
Samuel Sarmiento, MD, MPH, MBA*
Claire Temple-Oberle, MD, MSc, FRCS*
Oluseyi Aliu, MD*
Damon S. Cooney, MD, PhD*
Kristen P. Broderick, MD*
Justin M. Sacks, MD, MBA*
Michele A. Manahan, MD*
Gedge D. Rosson, MD*

Summary: Enhanced recovery after surgery pathways are well established in other surgical specialties but are relatively new in plastic surgery. These guidelines focus on improving patient care by incorporating evidence-based recommendations. Length of stay is shorter, and overall hospital costs are lower without compromising patient satisfaction. When care is standardized, ambiguity is removed and physician acceptance is improved. Yet, implementation can be challenging on an institutional level. The Johns Hopkins microsurgical breast reconstruction team identified areas of dogmatic dissonance during 3 focus groups to formalize an enhanced recovery pathway for microsurgical breast reconstruction. Six microsurgeons used nominal group technique to reach consensus. Four discussion points were identified: multidisciplinary buy-in, venous thromboembolism (VTE) chemoprophylaxis, early feeding, and dietary restrictions. Evidence-based recommendations and our enhanced recovery after surgery protocol are provided. (Plast Reconstr Surg Glob Open 2019;7:e1855; doi: 10.1097/GOX.0000000000001855; Published online 4 January 2019.)

BACKGROUND
ERAS pathways decrease length of stay, patient use of narcotics, and overall hospital costs.1-3 Patients benefit by walking sooner, sleeping better, and reporting a better postoperative experience.4 Until recently, a formalized ERAS-Society–endorsed pathway for breast reconstruction did not exist.5 Although these recommendations are now available to all, implementing them at an institutional level is not without challenges. Barriers to ERAS establishment have been published in specialties including colorectal, urology, and pediatric surgery.6-8 The Johns Hopkins microsurgical breast reconstruction team identified areas of dogmatic dissonance during 3 focus groups to formalize an enhanced recovery pathway that included pre-, peri-, and postoperative care (Table 1). Nominal group technique was used to reach consensus between the 6 microsurgeons involved.

MULTIDISCIPLINARY BUY-IN
Understanding the science of quality improvement (QI) and barriers to successful execution can be helpful for combating the adage “people resist change.”9,10 Change requires sound methodology, well-supported evidence, and a consensus of all members involved in the patient’s care.9 Through thorough discussion with our pain specialists, a multi-modal cocktail of analgesics was agreed upon. Our preoperative analgesic regimen includes celecoxib, gabapentin, and oral acetaminophen. Intraoperative transversus abdominis plane blocks are performed by our anesthesia team during the microsurgical anastomosis (following harvest of second flap if bilateral). With the two teams working concurrently, length of operation is not extended. Subjectively, our patients report better pain control in the postoperative period and will be formally studied in the next phase of our QI.

VTE CHEMOPROPHYLAXIS
Patency of anastomoses and prevention of venous thromboembolism are important components to consider during any microsurgical procedure. Unfractionated
### Table 1. ERAS Protocol for Microsurgical Breast Reconstruction as Implemented at the Department of Plastic & Reconstructive Surgery at The Johns Hopkins Hospital

| Orders               | Prior to Surgery | Day of Surgery – Preoperative Holding Area | Intraoperative |
|----------------------|------------------|--------------------------------------------|----------------|
| Labs Medications     | Normal preoperative work-up | Anti-emetics: Scopolamine patch (do not give with narrow/closed-angle glaucoma) | As needed Anti-emetics (PRN): Dexamethasone 4 mg IV after induction of anesthesia. Ondansetron 4–8 mg IV 30 minutes before end of case. Promethazine (Phenergan) 6 mg IV. |
|                      |                   | Analgesics: Acetaminophen 1 g PO (do not give with liver failure/ elevated liver enzymes). Celecoxib 400 mg PO (do not give with allergic-type reactions to sulfonamides). Gabapentin 600 mg PO (do not give with poor renal function). | Analgesics: Fentanyl or hydromorphone IV PRN. |
|                      |                   | Anti-coagulation: Heparin 5,000 units SC in preoperative holding area | Antibiotics: Cefazolin 2 g IV prior to incision, re-dose every 3 hours and 59 minutes or sooner. Clindamycin 600 mg IV for penicillin allergy, re-dose every 7 hours 59 minutes or sooner. |
|                      |                   | Fluids: Crystalloid IV 20–30 mL/kg minimum during case, avoid overload. | |
|                      |                   | Anesthesia: Avoid nitrous oxide. Avoid inhalational agents. Total IV anesthesia if possible. Circuit humidified low oxygen (<2 l/min). Anesthesia head turning guidelines for patients undergoing prolonged surgery. Transversus abdominis plane (TAP) blocks performed with ultra-sound guidance. | |
| Nursing and treatments |                   | Foley catheter, warming blanket, SCD’s to lower extremities, padding to protecting all prominent surfaces, pillow behind knees. | |
| Activity             |                   | | |
| Nutrition            |                   | | |
| Consents             | Preoperative anesthesia consultation | | |
| Teaching             | ERAS free flap education booklet provided to patient, which includes risks, benefits, and alternatives to surgery, expected length of stay, and postoperative course. | | |

*Guided by published ERAS pathways13,17,27,28, BID, twice a day; DVTp, deep vein thrombosis prophylaxis; IV, intravenous; PO, by mouth; POD, postoperative day; PRN, when necessary; SCD, sequential compression devices; TAP, transversus abdominis plane; TID, three times a day.
| Postoperative Day 0 | Postoperative Day 1 | Postoperative Day 2 | Postoperative Day 3 | Discharge |
|---------------------|---------------------|---------------------|---------------------|-----------|
| **Antiemetics (PRN):** Ondansetron (Zofran) 4 mg IV/PO q8h, Prochlorperazine (Phenergan) 5–12.5 mg IV (administer 15 minutes after ondansetron dose if patient has persistent nausea). | **Antiemetics:** Ondansetron (Zofran) 4 mg IV/PO q8h, PRN | **Antiemetics:** As before | **Antiemetics:** As before | **Discharge with following prescriptions:** Acetaminophen 650 mg PO q6h PRN for 7 days, ibuprofen 600 mg q6h PRN for 7 days. Tramadol 50 mg PO q4h PRN or oxycodone 30 mg q4h PRN (30 tabs max). Gabapentin 100 mg PO TID for 7 days (if tolerating well). |
| **Analgesics:** Routine medications: Acetaminophen 1 g PO q8h. Gabapentin 100 mg PO TID. Celecoxib 200 mg PO BID; PRN IV pain medications: Fentanyl 50 mcg IV q3h PRN for severe pain (pain scale rating 7–10 out of 10). Hydromorphone 0.5 mg IV q3h PRN for severe pain (pain scale rating 7–10 out of 10). PRN PO pain medications: Oxycodone 5 mg PO q4h PRN for moderate pain (pain scale rating 4–6 out of 10) | **Analgesics:** As before | **Analgesics:** As before | **Analgesics:** As before | **Discharge with following prescriptions:** Acetaminophen 650 mg PO q6h PRN for 7 days, ibuprofen 600 mg q6h PRN for 7 days. Tramadol 50 mg PO q4h PRN or oxycodone 30 mg q4h PRN (30 tabs max). Gabapentin 100 mg PO TID for 7 days (if tolerating well). |
| **Anti-coagulation:** Each patient assessed individually for DVTp risk: enoxaparin (Lovenox) 30 mg SC q12h | **Anti-coagulation:** Continue DVTp | **Anti-coagulation:** Continue DVTp | **Anti-coagulation:** Continue DVTp | **Discharge with following prescriptions:** Acetaminophen 650 mg PO q6h PRN for 7 days, ibuprofen 600 mg q6h PRN for 7 days. Tramadol 50 mg PO q4h PRN or oxycodone 30 mg q4h PRN (30 tabs max). Gabapentin 100 mg PO TID for 7 days (if tolerating well). |
| **Antibiotics:** Cefadroxil 1 g IV q8h x 24 hrs, administer 8 hours after last intraoperative dose. Clindamycin 600 mg q8h IV for penicillin allergy, administer 12 hours after last intraoperative dose. | **Flap checks q1h x 24 hours, q2h x 24 hours, q4h onward while in hospital. SCD’s to be worn when patient is in bed or chair, remove when ambulating. Record ins and outs including drain. Prime and empty drain PRN – 3 to 4 drains, right and left abdomen plus right and/or left breast. Inspect IV, drain and surgical sites as per nursing protocol. Hip flexion – continuous. Bedrest overnight. Sips of water | **Stool softener:** Docusate sodium (Colace) 100 mg PO BID. Senna (Senokot) 8.6 mg tabs – take two tablets qhs PRN. Glycerin suppository rectally once PRN. Foley out by 16:00 (nurses to activate order if appropriate). | **Stool softener:** As before | **Stool softener:** As before | **Discharge with following prescriptions:** Docusate sodium (Colace) 100 BID for 7 days. |
| **Fluids:** Crystalloid IV at maintenance, discontinue when drinking. | **Surgical sites as per nursing protocol.** | **Provide total assistance, transfer to chair in morning. Ambulate with one person assist until ambulating independently.** | **Ambulate three times per day, progress as tolerated Regular diet** | **Regular diet Physiotherapy** | **Physiotherapy outpatient referral No bra, drain care teaching, verify postoperative follow-up appointment scheduled within 7 days of discharge.** |
or low-molecular weight heparin can be administered in the preoperative holding area or can be given before or after the anastomosis is complete. Variations in this practice are often attributed to the surgeon’s previous training and experience or can be altered based on intraoperative events.11,12 There is no randomized control trial or comparative cohort study to discern a clinical difference in patient outcome and no clear algorithm exists for microsurgery.11 Our microsurgical team now routinely administers 5,000 units of subcutaneous heparin in the preoperative holding area. Following surgery, the patient is assessed using the 2005 Caprini VTE Risk Assessment Model Score, which is validated for plastic surgery.13 Typically, our patients have some of the risks factors in this model: increased age, major surgery (>45 minutes), or present or previous malignancy.14 Because of these factors and others such as difficulty ambulating in the postoperative period and potentially decreased venous return from the lower extremities due to tightened abdominal fascial closure, our free flap breast reconstruction patients are carefully considered for extended low molecular weight heparin treatment following discharge.15,16 Current recommendations for high risk patients suggests pharmacologic anticoagulation to continue at least 7 days.3,17,18 Self-administration can be easily taught to the patient before discharge. Although all of our microsurgeons use heparinized saline during vessel preparation and anastomosis, some of our microsurgeons start by flushing the flap despite no proven influence on flap failure.12 This particular maneuver likely has little influence on overall patient outcome and thus was not standardized amongst the surgical team members.

EARLY FEEDING

Resistance to early feeding was an identified discussion point. This hesitation stems mostly from the concern that flap compromise most commonly occurs in the acute period.19,20 Sips of water or ice chips the evening following surgery would not preclude a rapid return to the operating room should there be a flap concern. In other specialties, no benefit was found in maintaining nil per os the evening following surgery and even showed a reduction in complications and mortality when early feeding was initiated.21,22 Formally advancing the diet as tolerated in the morning after surgery is accepted as part of our enhanced recovery.

CAFFEINE AND CHOCOLATE

Caffeine’s mechanism of action on vascular tissue is complex and multi-faceted.23 To date, there is no conclusive evidence to support caffeine or chocolate as contributors to vasoconstriction.24 On a cellular level, caffeine induces greater expression of nitrous oxide, a vasodilator, on vascular endothelium25 and cocoa may have a suppressive effect on platelet reactivity.26 In a 2015 study by Noguechi et al.,27 however, caffeine intake was associated with decreased finger blood flow assessment by laser Doppler flow probe. Many surgeons continue to maintain a caffeine and chocolate-free diet in the postoperative period following free-flap reconstruction.13 One reason is that there is little harm to the patient in asking to modify their diet. There is increasing evidence suggesting vasopressor use in free flap surgery is safe, and these medications have a profound effect on vasoconstriction, and much more so than the effects of dietary caffeine.26 Consensus for a caffeine and chocolate-tolerated diet was not achieved for our free flap pathway following evidence-based group discussion.

RECOMMENDATIONS

Although ERAS is a reality for many specialties, it is relatively new for plastic surgery.27,28 As with every new protocol, there is resistance to change. Microsurgical breast reconstruction does not have the surgical case volume of colorectal surgery nor its complications and length of stay. That, in part, may contribute to difficulties in reaching a consensus on a particular ERAS pathway. Implementing an ERAS pathway is the ultimate QI practice, but to truly be an effective intervention, measuring success is crucial. A paucity in robust evidence of effectiveness may also hinder buy-in for certain individuals.

Our ERAS team consisted of 6 microsurgeons, a general surgeon, a clinical pathway nurse specialist, and an anesthesiologist. The proposed pathway required approval by the Johns Hopkins ERAS Steering Committee, the Patient Family Advisory Council, and Pharmacy and Therapeutics Committee. The proposed protocol was then incorporated into our electronic order sets (Epic Systems Corporation© – Epic Hyperspace 2017). Creating an enhanced recovery pathway that suits the needs of all team members can mean breaking tradition for some. Invited discussion regarding each attending’s concerns should take place with opportunity to introduce high-quality literature concerning proposed changes. Lastly, our recommendation includes prioritizing evidence-based practices to support high-value patient care and ensuring buy-in from all perioperative team members.

REFERENCES

1. Melnyk M, Casey RG, Black P, et al. Enhanced recovery after surgery (ERAS) protocols: time to change practice? Can Urol Assoc J. 2011;5:342–348.
2. Siotos C, Stergiou K, Naska A, et al. The impact of fast track protocols in upper gastrointestinal surgery: a meta-analysis of observational studies. Surg Endosc. 2018;32(5):183–192.
3. Ljungqvist O, Scott M, Fearon KC. Enhanced recovery after surgery: a review. JAMA Surg. 2017;152:292–298.
4. Dumestre DO, Webb CE, Temple-Oberle C. Improved recovery experience achieved for women undergoing implant-based breast reconstruction using an enhanced recovery after surgery model. Plast Reconstr Surg. 2017;139:550–559.
5. Temple-Oberle C, Shea-Budgell MA, Tan M, et al.; ERAS Society. Consensus review of optimal perioperative care in breast reconstruction: enhanced recovery after surgery (ERAS) society recommendations. *Plast Reconstr Surg*. 2017;139:1056e–1071e.

6. Lyon A, Solomon MJ, Harrison JD. A qualitative study assessing the barriers to implementation of enhanced recovery after surgery. *World J Surg*. 2014;38:1374–1380.

7. Leeds IL, Boss EF, George JA, et al. Preparing enhanced recovery after surgery for implementation in pediatric populations. *J Pediatr Surg*. 2016;51:2126–2129.

8. Danna BJ, Wood EL, Baack Kukreja JE, et al. The future of enhanced recovery for radical cystectomy: current evidence, barriers to adoption, and the next steps. *Urology*. 2016;96:62–68.

9. Heifetz R, Grashow A, Linsky M. The theory behind the practice. *The Practice of Adaptive Leadership*. Boston, Mass.: Harvard Business Press; 2009:19.

10. Pronovost PJ. Navigating adaptive challenges in quality improvement. *BMJ Qual Saf*. 2011;20:560–563.

11. Jokuszies A, Herold C, Niederbichler AD, et al. Anticoagulative strategies in reconstructive surgery—clinical significance and applicability. *Ger Med Sci*. 2012;10:Doc01.

12. Khouri RK, Cooley BC, Kunselman AR, et al. A prospective study of microvascular free-flap surgery and outcome. *Plast Reconstr Surg*. 1998;102:711–721.

13. Pannucci CJ, Bailey SH, Dreszer G, et al. Validation of the Caprini risk assessment model in plastic and reconstructive surgery patients. *J Am Coll Surg*. 2011;212:105–112.

14. Cubitt J, Barber Z, Khan AA, et al. Breast reconstruction with deep inferior epigastric perforator flaps. *Ann R Coll Surg Engl*. 2012;94:552–558.

15. Lemaine V, McCarthy C, Kaplan K, et al. Venous thromboembolism following microsurgical breast reconstruction: an objective analysis in 225 consecutive patients using low-molecular-weight heparin prophylaxis. *Plast Reconstr Surg*. 2011;127:1399–1406.

16. Momeni A, Tecce MG, Lanni MA, et al. Increased lower extremity venous stasis may contribute to deep venous thrombosis formation after microsurgical breast reconstruction—an ultrasonographic study. *J Reconstr Microsurg*. 2017;33:173–178.

17. Shea-Budgell M, Schrag C, Dumestre D, et al. Order sets for enhanced recovery after surgery protocol. *Plast Reconstr Surg Glob Open*. 2017;5:e1329.

18. Kim EK, Eom JS, Ahn SH, et al. The efficacy of prophylactic low-molecular-weight heparin to prevent pulmonary thromboembolism in immediate breast reconstruction using the TRAM flap. *Plast Reconstr Surg*. 2009;123:9–12.

19. Kroll SS, Schuster MA, Reece GP, et al. Timing of pedicle thrombosis and flap loss after free-tissue transfer. *Plast Reconstr Surg*. 1996;98:1230–1233.

20. Zelken JA, Berli JU. Coffee, tea, and chocolate after microsurgery: why not? *Ann Plast Surg*. 2015;74:139.

21. Weiland M, Casey RG, Black P, et al. Enhanced recovery after surgery (ERAS) protocols: time to change practice? *Can Urol Assoc J*. 2011;5:342–348.

22. Lewis SJ, Andersen HK, Thomas S. Early enteral nutrition within 24 h of intestinal surgery versus later commencement of feeding: a systematic review and meta-analysis. *J Gastrointest Surg*. 2009;13:569–575.

23. Echeverri D, Montes FR, Cabrera M, et al. Caffeine’s vascular mechanisms of action. *Int J Vasc Med*. 2010;2010:834060.

24. Rein D, Paglieroni TG, Pearson DA, et al. Cocoa and wine polyphenols modulate platelet activation and function. *J Nutr*. 2000;130:2120S–2126S.

25. Noguchi K, Matsuzaki T, Sakanashi M, et al. Effect of caffeine contained in a cup of coffee on microvascular function in healthy subjects. *J Pharmacol Sci*. 2015;127:271–272.

26. Swanson EW, Cheng HT, Susarla SM, et al. Intraoperative use of vasopressors is safe in head and neck free tissue transfer. *J Reconstr Microsurg*. 2016;32:87–93.

27. Sebai ME, Siotos C, Stone JP, et al. Enhanced recovery after surgery pathway for microsurgical breast reconstruction: a systematic review and meta-analysis. *Plast Reconstr Surg*. Accepted for publication.

28. Astanehe A, Temple-Oberle C, Nielsen M, et al. An enhanced recovery after surgery pathway for microvascular breast reconstruction is safe and effective. *Plast Reconstr Surg Glob Open*. 2018;6(1):p e1634.